OBJECTIVE: To evaluate the prescription of bisphosphonates in female nursing home residents aged 75 and older with a history of proximal femoral fracture. DESIGN: Observational descriptive study, led in Brest, France, between June and August 2015. SETTING: 12 nursing homes in Brest, France. PARTICIPANTS: Female nursing home residents, aged 75 and older, with a history of proximal femoral fracture were included. Exclusion criteria were contraindications to bisphosphonate treatment and residents restricted to bed and chair. MEASUREMENTS: The primary endpoint was the evaluation of prescription of bisphosphonates at the time of the study. The secondary endpoints were to evaluate vitamin D supplementation and factors associated with bisphosphonate prescription. RESULTS: 12 of the 116 included residents (10.3 %) received bisphosphonates. 66.4 % received vitamin D supplementation. CONCLUSION: Despite successive French and international recommendations, there is still a very important underuse of treatment by bisphosphonates in old institutionalized female patients with a very high risk of fracture.
OBJECTIVE: To evaluate the prescription of bisphosphonates in female nursing home residents aged 75 and older with a history of proximal femoral fracture. DESIGN: Observational descriptive study, led in Brest, France, between June and August 2015. SETTING: 12 nursing homes in Brest, France. PARTICIPANTS: Female nursing home residents, aged 75 and older, with a history of proximal femoral fracture were included. Exclusion criteria were contraindications to bisphosphonate treatment and residents restricted to bed and chair. MEASUREMENTS: The primary endpoint was the evaluation of prescription of bisphosphonates at the time of the study. The secondary endpoints were to evaluate vitamin D supplementation and factors associated with bisphosphonate prescription. RESULTS: 12 of the 116 included residents (10.3 %) received bisphosphonates. 66.4 % received vitamin D supplementation. CONCLUSION: Despite successive French and international recommendations, there is still a very important underuse of treatment by bisphosphonates in old institutionalized female patients with a very high risk of fracture.
Authors: Seema Parikh; M Alan Brookhart; Margaret Stedman; Jerry Avorn; Helen Mogun; Daniel H Solomon Journal: Bone Date: 2011-02-21 Impact factor: 4.398
Authors: P N Sambrook; I D Cameron; J S Chen; L M March; J M Simpson; R G Cumming; M J Seibel Journal: Osteoporos Int Date: 2010-10-20 Impact factor: 4.507
Authors: C Colón-Emeric; K W Lyles; D A Levine; P House; A Schenck; J Gorospe; M Fermazin; K Oliver; J Alison; N Weisman; A Xie; J R Curtis; K Saag Journal: Osteoporos Int Date: 2006-11-21 Impact factor: 4.507
Authors: R Lindsay; S L Silverman; C Cooper; D A Hanley; I Barton; S B Broy; A Licata; L Benhamou; P Geusens; K Flowers; H Stracke; E Seeman Journal: JAMA Date: 2001-01-17 Impact factor: 56.272
Authors: Dana Bliuc; Nguyen D Nguyen; Vivienne E Milch; Tuan V Nguyen; John A Eisman; Jacqueline R Center Journal: JAMA Date: 2009-02-04 Impact factor: 56.272